A950210 Stock Overview
Prestige BioPharma Limited, a biopharmaceutical company, engages in the research and development and marketing of biosimilars, first-in-class antibody drugs, and vaccines.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Prestige BioPharma Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩8,000.00 |
| 52 Week High | ₩14,920.00 |
| 52 Week Low | ₩7,850.00 |
| Beta | 1.15 |
| 1 Month Change | -4.65% |
| 3 Month Change | -1.96% |
| 1 Year Change | -19.52% |
| 3 Year Change | -76.37% |
| 5 Year Change | n/a |
| Change since IPO | -75.61% |
Recent News & Updates
Recent updates
Shareholder Returns
| A950210 | KR Biotechs | KR Market | |
|---|---|---|---|
| 7D | -0.4% | 0.3% | -0.4% |
| 1Y | -19.5% | 5.7% | 4.5% |
Return vs Industry: A950210 underperformed the KR Biotechs industry which returned 5.7% over the past year.
Return vs Market: A950210 underperformed the KR Market which returned 4.5% over the past year.
Price Volatility
| A950210 volatility | |
|---|---|
| A950210 Average Weekly Movement | 4.5% |
| Biotechs Industry Average Movement | 8.4% |
| Market Average Movement | 5.2% |
| 10% most volatile stocks in KR Market | 11.8% |
| 10% least volatile stocks in KR Market | 2.4% |
Stable Share Price: A950210 has not had significant price volatility in the past 3 months.
Volatility Over Time: A950210's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | n/a | So-Yeon Park | www.prestigebiopharma.com |
Prestige BioPharma Limited, a biopharmaceutical company, engages in the research and development and marketing of biosimilars, first-in-class antibody drugs, and vaccines. The company primarily engages in the development of biosimilars, including Trastuzumab, which is under regulatory review for breast and gastric cancer; Bevacizumab, in phase 3 clinical study for solid tumours; Adalimumab, in phase 1 clinical study for arthritis. It is developing first-in-class antibody therapeutics, such as monoclonal antibodies, bispecific antibodies, and fusion antibodies for life-threatening diseases; vaccines for COVID-19 virus; and diagnostic kits for the detection of pancreatic adenocarcinoma upregulated factor.
Prestige BioPharma Limited Fundamentals Summary
| A950210 fundamental statistics | |
|---|---|
| Market cap | ₩96.15b |
| Earnings (TTM) | -₩46.03b |
| Revenue (TTM) | ₩348.79m |
275.7x
P/S Ratio-2.1x
P/E RatioIs A950210 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A950210 income statement (TTM) | |
|---|---|
| Revenue | ₩348.79m |
| Cost of Revenue | ₩33.94m |
| Gross Profit | ₩314.85m |
| Other Expenses | ₩46.34b |
| Earnings | -₩46.03b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.83k |
| Gross Margin | 90.27% |
| Net Profit Margin | -13,196.80% |
| Debt/Equity Ratio | 21.4% |
How did A950210 perform over the long term?
See historical performance and comparison